Increased expression of CD133 is a strong predictor of poor outcome in stage I colorectal cancer patients

被引:13
作者
Bonetti, Luca Reggiani [2 ]
Migaldi, Mario [2 ]
Caredda, Emanuele
Boninsegna, Alma
De Leon, Maurizio Ponz [3 ]
Di Gregorio, Carmela [2 ]
Barresi, Valeria [4 ]
Scannone, Domenico
Danese, Silvio [5 ]
Cittadini, Achille
Sgambato, Alessandro [1 ]
机构
[1] Univ Cattolica Sacro Cuore, Ist Patol Gen, Ctr Ric Oncol Giovanni XXIII, I-00168 Rome, Italy
[2] Univ Modena & Reggio Emilia, Sez Anat Patol, Dipartimento Misto Anat Patol & Med Legale, Modena, Italy
[3] Univ Modena & Reggio Emilia, Dipartimento Med & Specialita Med, Modena, Italy
[4] Univ Messina, Dipartimento Patol Umana, Messina, Italy
[5] Ist Clin Humanitas, Dept Gastroenterol, Milan, Italy
关键词
adjuvant therapy; cancer stem cells; CD133; prognosis; stage I colon cancer; LYMPH-NODE MICROMETASTASES; COLON-CANCER; PROGNOSTIC MARKER; STEM-CELLS; SURVIVAL; TUMORIGENESIS; CARCINOMA; DUKES;
D O I
10.3109/00365521.2012.694904
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Objective. Stage I colorectal carcinomas display a highly variable behavior which is not accurately predicted by the available prognostic markers. CD133 is considered a useful marker to identify the so-called cancer stem cells in colorectal cancers (CRCs) and its expression has been shown to have prognostic significance in CRC patients. This study aimed to verify whether immunohistochemical evaluation of CD133 might correlate with the progression risk of stage I CRC patients. Material and methods. Expression levels of the CD133 molecule were analyzed and compared in two series of stage I surgically resected CRC patients showing disease progression and death for the disease and patients with no evidence of disease progression after at least 6 years after surgery. Results. A positive staining for CD133 was detected in 52% of the cases with poor prognosis and only in 9% of the group with good prognosis, and this difference was highly significant (p < 0.001). A significant correlation was detected between CD133 expression and histological parameters, such as tumor budding, vascular invasion, and presence of lymph node micrometastases but not tumor grading, gender, and age. Disease-free survival and cancer-specific survival of CD133 negative tumors were significantly longer compared to positive cases. In multivariate analyses, CD133 staining confirmed to be a predictor of shorter survival independent from vascular invasion but not from lymph nodes micrometastases. Conclusions. These findings demonstrate that CD133 immunostaining is a useful predictor of high risk progression in stage I CRC patients and might help to identify patients eligible for adjuvant chemotherapy.
引用
收藏
页码:1211 / 1217
页数:7
相关论文
共 50 条
[21]   Is CD133 mRNA Expression a Prognostic Factor in Colorectal Cancer? [J].
Hayama, Tamuro ;
Watanabe, Toshiaki ;
Iinuma, Hisae .
JOURNAL OF SURGICAL ONCOLOGY, 2011, 104 (01) :110-110
[22]   CD133 Expression in Medullary Thyroid Cancer Cells Identifies Patients with Poor Prognosis [J].
Cordero-Barreal, Alfonso ;
Caleiras, Eduardo ;
Lopez de Maturana, Evangelina ;
Monteagudo, Maria ;
Martinez-Montes, Angel M. ;
Leton, Rocio ;
Gil, Eduardo ;
Alvarez-Escola, Cristina ;
Regojo, Rita M. ;
Andia, Victor ;
Marazuela, Monica ;
Guadalix, Sonsoles ;
Calatayud, Maria ;
Robles-Diaz, Luis ;
Aguirre, Miguel ;
Cano, Juana M. ;
Angel Diaz, Jose ;
Saavedra, Pilar ;
Lamas, Cristina ;
Azriel, Sharona ;
Sastre, Julia ;
Aller, Javier ;
Leandro-Garcia, Luis J. ;
Calsina, Bruna ;
Maria Roldan-Romero, Juan ;
Santos, Maria ;
Lanillos, Javier ;
Cascon, Alberto ;
Rodriguez-Antona, Cristina ;
Robledo, Mercedes ;
Montero-Conde, Cristina .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2020, 105 (11) :1-14
[23]   CD133 expression is an independent prognostic marker for low survival in colorectal cancer [J].
Horst, D. ;
Kriegl, L. ;
Engel, J. ;
Kirchner, T. ;
Jung, A. .
BRITISH JOURNAL OF CANCER, 2008, 99 (08) :1285-1289
[24]   CD133 expression is an independent prognostic marker for low survival in colorectal cancer [J].
D Horst ;
L Kriegl ;
J Engel ;
T Kirchner ;
A Jung .
British Journal of Cancer, 2008, 99 :1285-1289
[25]   Differential Clinical Benefits of 5-Fluorouracil-based Adjuvant Chemotherapy for Patients with Stage III Colorectal Cancer According to CD133 Expression Status [J].
Shikina, Atsushi ;
Shinto, Eiji ;
Hashiguchi, Yojiro ;
Ueno, Hideki ;
Naito, Yoshihisa ;
Okamoto, Koichi ;
Kubo, Toru ;
Fukazawa, Satomi ;
Yamamoto, Junji ;
Hase, Kazuo .
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2014, 44 (01) :42-48
[26]   CD133 expression is not an independent prognostic factor in stage II and III colorectal cancer but may predict the better outcome in patients with adjuvant therapy [J].
Khalilullah Mia-Jan ;
So Young Jung ;
Ik-Yong Kim ;
Sung Soo Oh ;
EunHee Choi ;
Sei Jin Chang ;
Tae Young Kang ;
Mee-Yon Cho .
BMC Cancer, 13
[27]   Expression of CD133 in endometrial cancer cells and its implications [J].
Ding, Dah-Ching ;
Liu, Hwan-Wun ;
Chang, Yu-Hsun ;
Chu, Tang-Yuan .
JOURNAL OF CANCER, 2017, 8 (11) :2142-2153
[28]   Upregulated CD133 expression in tumorigenesis of colon cancer cells [J].
Yang, Zhi-Li ;
Zheng, Qi ;
Yan, Jun ;
Pan, Ye ;
Wang, Zhi-Gang .
WORLD JOURNAL OF GASTROENTEROLOGY, 2011, 17 (07) :932-937
[29]   Association of Vasculogenic Mimicry Formation and CD133 Expression with Poor Prognosis in Ovarian Cancer [J].
Liang, Jun ;
Yang, Bo ;
Cao, Qinying ;
Wu, Xiaohua .
GYNECOLOGIC AND OBSTETRIC INVESTIGATION, 2016, 81 (06) :529-536
[30]   CD133 expression predicts lung metastasis and poor prognosis in osteosarcoma patients: A clinical and experimental study [J].
He, Aina ;
Qi, Weixiang ;
Huang, Yujing ;
Feng, Tao ;
Chen, Jie ;
Sun, Yuanjue ;
Shen, Zan ;
Yao, Yang .
EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2012, 4 (03) :435-441